News

ImmunoGenesis, a clinical-stage biotech company developing innovative, science-driven immunotherapies, today announced the appointment of Claudio Dansky Ullmann, M.D. as Chief Medical Officer. Dr. Dansky Ullmann will support development of the Company’s cytotoxic immune checkpoint inhibitor, IMGS-001, and ImmunoGenesis’ multi-mechanism strategy aimed at addressing the pathology of immune-excluded tumors by overcoming immune exclusion.

ImmunoGenesis, a clinical-stage biotech company developing innovative, science-driven immunotherapies, today announced that it will present a poster at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2026, which is being held from April 17–22, 2026, in San Diego, CA.

BostonGene, developer of the leading AI foundation model for tumor and immune biology, and ImmunoGenesis, a clinical-stage biotech company developing innovative, science-driven immunotherapies, today announced a strategic partnership to accelerate the clinical development of IMGS-001, the company’s lead program.

IMGS-001, the company’s lead program, is a cytotoxic immune checkpoint inhibitor targeting PD-L1 and PD-L2 and is being studied in a phase 1a/b dose escalation and expansion trial (NCT06014502). The focus of this CPRIT grant – which is the Company’s second grant from CPRIT – will be to support the phase 1b dose expansion portion of the trial across multiple solid tumor cohorts.

Initial meeting of Scientific Advisory Board (SAB) convened to discuss the first-in-human phase 1a/1b clinical trial of IMGS-001, a dual-specific PD-L1/PD-L2 antibody with cytotoxic killing function designed to treat the many “immune-excluded” cancers that are resistant to existing immunotherapies.